Folate Pathway Genetic Polymorphisms are Related to Attention Disorders in Childhood Leukemia Survivors

Journal of Pediatrics

Volumn 152, Issue 1, 2008, Pages 101-105

  Krull, Kevin R ^a,b   Brouwers, Pim ^b,c,d   Jain, Neelam ^a,b   Zhang, Linna ^b,c   Bomgaars, Lisa ^b,c   Dreyer, ZoAnn ^b,c   Mahoney, Donald ^b,c   Bottomley, Sarah ^c   Okcu, M Fatih ^b,c,e  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e Childhood Cancer Epidemiology and Prevention Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 DIMETHYLENETETRAHYDROREDUCTASE; ENZYME; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; FOLIC ACID BLOOD LEVEL; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVOR; TEST RETEST RELIABILITY; TREATMENT RESPONSE;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; FEMALE; FOLIC ACID ANTAGONISTS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NAD+); PARENTS; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; QUESTIONNAIRES; SURVIVORS;

EID: 37249044154     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2007.05.047     Document Type: Article

References (34)

1. Hewitt M., Weiner S.L., and Simone J.V. Childhood Cancer Survivorship: Improving Care and Quality of Life (2003), National Academy of Sciences, Washington, DC
2. Moleski M. Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol 15 (2000) 603-630
3. Mulhern R.K., Fairclough D., and Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol 9 (1991) 1348-1356
4. Montour-Proulx I., Kuehn S.M., Keene D.L., Barrowman N.J., Hsu E., Matzinger M.A., et al. Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. J Child Neurol 20 (2005) 129-133
5. Espy K.A., Moore I.M., Kaufmann P.M., Kramer J.H., Matthay K., and Hutter J.J. Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. J Pediatr Psychol 26 (2001) 1-9
6. Kaemingk K.L., Carey M.E., Moore I.M., Herzer M., and Hutter J.J. Math weaknesses in survivors of acute lymphoblastic leukemia compared with healthy children. Child Neuropsychol 10 (2004) 14-23
7. Brown R.T., Madan-Swain A., Pais R., Lambert R.G., Sexson S., and Ragab A. Chemotherapy for acute lymphocytic leukemia: cognitive and academic sequelae. J Pediatr 121 (1992) 885-889
8. Carey M.E., Hockenberry M.J., Moore I.M., Hutter J.J., Krull K.R., Pasvogel A., et al. Brief report: effect of intravenous methotrexate dose and infusion rate on neuropsychological function one year after diagnosis of acute lymphoblastic leukemia. J Pediatr Psychol 32 (2007) 189-193
9. Paakko E., Harila-Saari A., Vanionpaa L., Himanen S., Pyhtinen J., and Lanning M. White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: correlation with neuropsychological findings. Med Pediatr Oncol 35 (2000) 456-461
10. Waber D.P., Carpentieri S.C., Klar N., Silverman L.B., Schwenn M., Hurwitz C.A., et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol 22 (2000) 206-213
11. Wolkowitz O.M., Lupien S.J., Bigler E., Levin R.B., and Canick J. The "steroid dementia syndrome": an unrecognized complication of glucocorticoid treatment. Ann N Y Acad Sci 1032 (2004) 191-194
12. Brouwers P. Study of the neurobehavioral consequences of childhood cancer: entering the genomic era?. Commentary. J Pediatr Psychol 30 (2005) 79-84
13. Kingma A., Van Dommelen R.I., Mooyaart E.L., Wilmink J.T., Deelman B.G., and Kamps W.A. No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study. J Pediatr Hematol Oncol 24 (2002) 106-114
14. Rodgers J., Marckus R., Kearns P., and Windebank K. Attentional ability among survivors of leukaemia treated without cranial irradiation. Arch Dis Child 88 (2003) 147-150
15. Miketova P., Kaemingk K., Hockenberry M., Pasvogel A., Hutter J., Krull K., et al. Oxidative changes in cerebral spinal fluid phosphatidylcholine during treatment for acute lymphoblastic leukemia. Biol Res Nurs 6 (2005) 187-195
16. Goldman I.D., and Matherly L.H. The cellular pharmacology of methotrexate. Pharmacol Ther 28 (1985) 77-102
17. Ogino S., and Wilson R.B. Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single-nucleotide polymorphisms: a meta-analysis. J Hum Genet 48 (2003) 1-7
18. Lipton S.A., and Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330 (1994) 613-622
19. Gadow K.D., and Sprafkin J. Child Symptom Inventory (1997), Checkmate Plus, Stony Brook, NY
20. Sprafkin J., Gadow K.D., Salisbury H., Schneider J., and Loney J. Further evidence of reliability and validity of the Child Symptom Inventory 4 parent checklist in clinically referred boys. J Clin Child Adolesc Psychol 31 (2002) 513-524
21. Ferguson G.A. Statistical Analysis in Psychology & Education. 4th edition (1976), McGraw-Hill, New York
22. Uckun F.M., Stork L., Seibel N., Sarquis M., Bedros C., Sather H., et al. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia. Clin Cancer Res 6 (2000) 3123-3130
23. Krull K.R., Jain N., Brouwers P., Law R., Bottomley S., and Dreyer Z. Childhood leukemia survivors: patterns of ADHD symptomology. J Int Neuropsychol Soc 9 (2003) 261
24. Krajinovic M., Robaey P., Chiasson S., Lemieux-Blanchard E., Rouillard M., Primeau M., et al. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics 6 (2005) 293-302
25. Robien K., Boynton A., and Ulrich C.M. Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 6 (2005) 673-689
26. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
27. Botto L.D., and Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 151 (2000) 862-877
28. Robien K., and Ulrich C.M. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 157 (2003) 571-582
29. Schwahn B., and Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenom 1 (2001) 189-201
30. Gimpel G.A., and Kuhn B.R. Maternal report of attention deficit hyperactivity disorder symptoms in preschool children. Child Care Health Dev 26 (2000) 163-179
31. Byrne J.M., Bawden H.N., Beattie T.L., and DeWolfe N.A. Preschoolers classified as having attention-deficit hyperactivity disorder (ADHD): DSM-IV symptom endorsement pattern. J Child Neurol 15 (2000) 533-538
32. Maitland-van der Zee A.H., de Boer A., and Leufkens H.G. The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol 410 (2000) 121-130
33. Vesell E.S. Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 40 (2000) 930-938
34. Relling M.V., and Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 1 (2001) 99-108